Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
92% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. SYN: No Debt )
SYN' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
75% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
SYN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 64.38
M-Score: -5.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -80.87
SYN's ROE (%) is ranked higher than
58% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. SYN: -80.87 )
SYN' s 10-Year ROE (%) Range
Min: -2657.14   Max: -34.78
Current: -80.87

-2657.14
-34.78
ROA (%) -75.76
SYN's ROA (%) is ranked higher than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. SYN: -75.76 )
SYN' s 10-Year ROA (%) Range
Min: -1575   Max: -32.75
Current: -75.76

-1575
-32.75
ROC (Joel Greenblatt) (%) -2053.08
SYN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. SYN: -2053.08 )
SYN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3613.84   Max: -124.34
Current: -2053.08

-3613.84
-124.34
Revenue Growth (%) -100.00
SYN's Revenue Growth (%) is ranked higher than
53% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SYN: -100.00 )
SYN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (%) 108.00
SYN's EBITDA Growth (%) is ranked higher than
99% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. SYN: 108.00 )
SYN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 108
Current: 108

0
108
EPS Growth (%) 65.10
SYN's EPS Growth (%) is ranked higher than
99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. SYN: 65.10 )
SYN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.1
Current: 65.1

0
65.1
» SYN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SYN Guru Trades in Q2 2013

Chuck Royce 428,669 sh (New)
» More
Q3 2013

SYN Guru Trades in Q3 2013

Chuck Royce 428,669 sh (unchged)
» More
Q4 2013

SYN Guru Trades in Q4 2013

Chuck Royce 778,000 sh (+81.49%)
» More
Q1 2014

SYN Guru Trades in Q1 2014

Chuck Royce 276,000 sh (-64.52%)
» More
» Details

Insider Trades

Latest Guru Trades with SYN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.40
SYN's P/B is ranked higher than
66% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. SYN: 7.40 )
SYN' s 10-Year P/B Range
Min: 2.78   Max: 18.11
Current: 7.4

2.78
18.11
EV-to-EBIT -6.08
SYN's EV-to-EBIT is ranked higher than
56% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SYN: -6.08 )
SYN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -6.08

Current Ratio 16.15
SYN's Current Ratio is ranked higher than
94% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. SYN: 16.15 )
SYN' s 10-Year Current Ratio Range
Min: 0.03   Max: 58.44
Current: 16.15

0.03
58.44
Quick Ratio 16.15
SYN's Quick Ratio is ranked higher than
95% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SYN: 16.15 )
SYN' s 10-Year Quick Ratio Range
Min: 0.03   Max: 58.44
Current: 16.15

0.03
58.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.20
SYN's Price/Net Cash is ranked higher than
85% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. SYN: 8.20 )
SYN' s 10-Year Price/Net Cash Range
Min: 0.72   Max: 27.57
Current: 8.2

0.72
27.57
Price/Net Current Asset Value 8.20
SYN's Price/Net Current Asset Value is ranked higher than
84% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. SYN: 8.20 )
SYN' s 10-Year Price/Net Current Asset Value Range
Min: 0.72   Max: 27.57
Current: 8.2

0.72
27.57
Price/Tangible Book 7.40
SYN's Price/Tangible Book is ranked higher than
72% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. SYN: 7.40 )
SYN' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 25
Current: 7.4

0.56
25
Price/Median PS Value 0.90
SYN's Price/Median PS Value is ranked higher than
59% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. SYN: 0.90 )
SYN' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 0.81
Current: 0.9

0.5
0.81
Forward Rate of Return (Yacktman) -172.82
SYN's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. SYN: -172.82 )
SYN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -172.82

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SFYB.Germany
Synthetic Biologics Inc. was incorporated in the State of Nevada. The company is a biotechnology company engaged in the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. It is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics.
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for... Jul 21 2014
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for... Jul 21 2014
Synthetic Biologics forms CAB to support development of SYN-004 Jun 30 2014
Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program Jun 30 2014
Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves... Jun 25 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 13 2014
Synthetic Biologics and Enterome Bioscience Collaborate on Microbiome Research to Support Synthetic... Jun 10 2014
Synthetic Biologics and Enterome Bioscience Collaborate on Microbiome Research to Support Synthetic... Jun 10 2014
[video] 3D printing a leader in healthcare disruption May 28 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 27 2014
SYNTHETIC BIOLOGICS, INC. Financials May 23 2014
Synthetic Biologics to Present at the 3rd Annual Marcum LLP MicroCap Conference May 20 2014
Why I'm Short Synthetic Biologics After Phase II Relapsing-Remitting MS Data May 19 2014
Why Synthetic Biologics (SYN) Stock Is Surging Today May 15 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 15 2014
Synthetic Biologics' (SYN) CEO, Jeff Riley on Q1 2014 Results - Earnings Call Transcript May 15 2014
Q1 2014 Synthetic Biologics Inc Earnings Release - Time Not Supplied May 15 2014
Synthetic Biologics reports Q1 EPS (7c), consensus (8c) May 15 2014
Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights May 15 2014
Synthetic Biologics to Report First Quarter 2014 Financial Results May 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide